User login
Key clinical point: In combination with 6 months of fluoropyrimidine therapy, 3 vs 6 months of oxaliplatin treatment (3- vs 6-month arm, respectively) is noninferior in patients with high-risk stage II or III colorectal cancer (CRC).
Major finding: The 3- vs 6-month arm showed significantly lower any-grade neuropathy rates (58.3% vs 69.5%; P < .0001) and comparable 3-year disease-free survival rates (84.7% vs 83.7%) with a hazard ratio of 0.953 (Pnoninferiority = .0065), which was within the noninferiority margin of 1.25.
Study details: Findings are from a multicenter, phase 3 trial that included 1788 patients with high-risk stage II or III CRC who were randomly assigned to receive 3 (n = 893) or 6 (n = 895) months of oxaliplatin with 6 months of fluoropyrimidine therapy.
Disclosures: This study was sponsored by the Colorectal Cancer Committee of the Korean Cancer Study Group and Sanofi. Some authors declared serving as consultants or advisors for or receiving research funding from various sources, including Sanofi.
Source: Kim ST et al. Oxaliplatin (3 months v 6 months) with 6 months of fluoropyrimidine as adjuvant therapy in patients with stage II/III colon cancer: KCSG CO09-07. J Clin Oncol. 2022 (Jun 30). Doi: 10.1200/JCO.21.02962
Key clinical point: In combination with 6 months of fluoropyrimidine therapy, 3 vs 6 months of oxaliplatin treatment (3- vs 6-month arm, respectively) is noninferior in patients with high-risk stage II or III colorectal cancer (CRC).
Major finding: The 3- vs 6-month arm showed significantly lower any-grade neuropathy rates (58.3% vs 69.5%; P < .0001) and comparable 3-year disease-free survival rates (84.7% vs 83.7%) with a hazard ratio of 0.953 (Pnoninferiority = .0065), which was within the noninferiority margin of 1.25.
Study details: Findings are from a multicenter, phase 3 trial that included 1788 patients with high-risk stage II or III CRC who were randomly assigned to receive 3 (n = 893) or 6 (n = 895) months of oxaliplatin with 6 months of fluoropyrimidine therapy.
Disclosures: This study was sponsored by the Colorectal Cancer Committee of the Korean Cancer Study Group and Sanofi. Some authors declared serving as consultants or advisors for or receiving research funding from various sources, including Sanofi.
Source: Kim ST et al. Oxaliplatin (3 months v 6 months) with 6 months of fluoropyrimidine as adjuvant therapy in patients with stage II/III colon cancer: KCSG CO09-07. J Clin Oncol. 2022 (Jun 30). Doi: 10.1200/JCO.21.02962
Key clinical point: In combination with 6 months of fluoropyrimidine therapy, 3 vs 6 months of oxaliplatin treatment (3- vs 6-month arm, respectively) is noninferior in patients with high-risk stage II or III colorectal cancer (CRC).
Major finding: The 3- vs 6-month arm showed significantly lower any-grade neuropathy rates (58.3% vs 69.5%; P < .0001) and comparable 3-year disease-free survival rates (84.7% vs 83.7%) with a hazard ratio of 0.953 (Pnoninferiority = .0065), which was within the noninferiority margin of 1.25.
Study details: Findings are from a multicenter, phase 3 trial that included 1788 patients with high-risk stage II or III CRC who were randomly assigned to receive 3 (n = 893) or 6 (n = 895) months of oxaliplatin with 6 months of fluoropyrimidine therapy.
Disclosures: This study was sponsored by the Colorectal Cancer Committee of the Korean Cancer Study Group and Sanofi. Some authors declared serving as consultants or advisors for or receiving research funding from various sources, including Sanofi.
Source: Kim ST et al. Oxaliplatin (3 months v 6 months) with 6 months of fluoropyrimidine as adjuvant therapy in patients with stage II/III colon cancer: KCSG CO09-07. J Clin Oncol. 2022 (Jun 30). Doi: 10.1200/JCO.21.02962